lanadelumab-flyo
Drug Details
- Generic Name
- lanadelumab-flyo
- Brand Names
- TAKHZYRO
- Application Number
- BLA761090
- Sponsor
- Takeda Pharmaceuticals America, Inc.
- NDC Codes
- 4
- Dosage Forms
- SOLUTION, INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- LANADELUMAB
Indications and Usage
1 INDICATIONS AND USAGE TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 )